Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Ivermectin  COVID-19 treatment studies for Ivermectin  C19 studies: Ivermectin  Ivermectin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 14% Improvement Relative Risk Respiratory deterioration.. 9% Discharge -37% Hospitalization time -20% primary Beltran Gonzalez et al. Ivermectin RCT LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 73 patients in Mexico Multiple inconsistencies and issues, see notes Beltran Gonzalez et al., Infectious Disease Repo.., doi:10.3390/idr14020020 Favors ivermectin Favors control
Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial
Beltran Gonzalez et al., Infectious Disease Reports, doi:10.3390/idr14020020 (date from earlier preprint)
Beltran Gonzalez et al., Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized.., Infectious Disease Reports, doi:10.3390/idr14020020 (date from earlier preprint)
Feb 2021   Source   PDF  
  All Studies   Meta
RCT late stage severe condition (93% SOFA ≥ 2, 96% APACHE ≥ 8) high comorbidity hospitalized patients in Mexico with 36 low dose ivermectin and 37 control patients not finding significant differences. NCT04391127 (history).
Another study reports results on a larger group of patients in the same hospital, showing ivermectin mortality RR 0.81 [0.53-1.24] [Guzman].
Questions have been raised about this study and the early termination of the study and discontinuation of treatments, because the hospital statistics show a dramatically lower (~75%) case fatality rate during the period of the study [] (data from []).
Several other inconsistencies have been reported [Chamie].
Although the data from this study is reported to be available and has been shared with an anti-treatment group, independent researchers have been unable to obtain the data for verification [Chamie,].
This study is excluded in the after exclusion results of meta analysis: major inconsistencies reported and the data is no longer available, although the authors state that it is available, and have shared it with an anti-treatment group.
risk of death, 14.4% lower, RR 0.86, p = 1.00, treatment 5 of 36 (13.9%), control 6 of 37 (16.2%), NNT 43.
risk of respiratory deterioration or death, 8.6% lower, RR 0.91, p = 1.00, treatment 8 of 36 (22.2%), control 9 of 37 (24.3%), NNT 48.
risk of no hospital discharge, 37.0% higher, RR 1.37, p = 0.71, treatment 4 of 36 (11.1%), control 3 of 37 (8.1%).
hospitalization time, 20.0% higher, relative time 1.20, p = 0.43, treatment 36, control 37, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Beltran Gonzalez et al., 23 Feb 2021, Double Blind Randomized Controlled Trial, Mexico, peer-reviewed, mean age 53.8, 13 authors, average treatment delay 7.0 days, dosage 12mg single dose, 18mg for patients >80kg.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Abstract: Article Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial Jose Lenin Beltran Gonzalez 1 , Mario González Gámez 1, *, Emanuel Antonio Mendoza Enciso 1 , Ramiro Josue Esparza Maldonado 1 , Daniel Hernández Palacios 1 , Samuel Dueñas Campos 1 , Itzel Ovalle Robles 1 , Mariana Jocelyn Macías Guzmán 1 , Andrea Lucia García Díaz 1 , César Mauricio Gutiérrez Peña 1 , Lucila Martinez Medina 2 , Victor Antonio Monroy Colin 2 and Jose Manuel Arreola Guerra 1, * 1 2 *   Citation: Beltran Gonzalez, J.L.; González Gámez, M.; Mendoza Enciso, E.A.; Esparza Maldonado, R.J.; Hernández Palacios, D.; Dueñas Campos, S.; Robles, I.O.; Macías Guzmán, M.J.; García Díaz, A.L.; Gutiérrez Peña, C.M.; et al. Efficacy and Safety of Ivermectin and Hydroxychloroquine in Patients with Severe COVID-19: A Randomized Controlled Trial. Infect. Dis. Rep. 2022, 14, 160–168. 10.3390/idr14020020 Academic Editor: Nicola Petrosillo Received: 17 January 2022 Accepted: 25 February 2022 Published: 3 March 2022 Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in Internal Medicine Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico; (J.L.B.G.); (E.A.M.E.); (R.J.E.M.); (D.H.P.); (S.D.C.); (I.O.R.); (M.J.M.G.); (A.L.G.D.); (C.M.G.P.) Pediatrics Department Centenario Hospital Miguel Hidalgo, Aguascalientes 20259, Mexico; (L.M.M.); (V.A.M.C.) Correspondence: (M.G.G.); (J.M.A.G.) Abstract: During the first year of the COVID-19 pandemic, unauthorized drugs were widely used. Ivermectin and hydroxychloroquine are drugs that inhibit viral replication in vitro and that have been used in several medical centers. This clinical trial analyzes their efficacy in hospitalized patients with moderate COVID-19. Methods: This a controlled, clinical, randomized, double-blind trial that included hospitalized patients with COVID-19-induced pneumonia, without severe respiratory failure. Patients were randomized to one of three groups: Group 1—hydroxychloroquine, 400 mg every 12 h on the first day and, subsequently, 200 mg every 12 h for 4 days; Group 2—ivermectin, 12 mg or 18 mg, according to patient weight; and Group 3—placebo. At inclusion, blood samples for arterial blood gases and biochemical markers were obtained. The primary outcome was established as the length of stay due to patient improvement and the rate of respiratory deterioration or death. Results: During the month of August 2020, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment process and analyzed the data that was available at the time. One hundred and six (106) patients with an average age of 53 yrs (±16.9) were included, with a greater proportion of males (n = 66, 62.2%). Seventy-two percent (72%) (n = 76) had an associated comorbidity. Ninety percent (90%) of patients were discharged due to improvement (n = 96). The average duration of hospitalization was 6 days (IQR, 3–10). No difference in hospitalization duration was found between the treatment groups (Group1: 7 vs. Group 2: 6 vs. Group 3: 5, p = 0.43)..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop